MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)*
Organization & Developments: Amylyx Pharmaceuticals
Parents
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)*
Children
*Biopharmaceutical company developing therapies for treatment of amyotrophic lateral sclerosis (ALS), and range of neurodegenerative diseases by keeping neurons alive
2022: Amylyx ALS Drug Approval: Unexpected, Welcome, And Conditional - May Put Share Price In Stasis_ seekingalpha.com
2022: Amylyx: AdComm Decision Due Today Unlikely To Increase ALS Drug Approval Chances_seekingalpha.com
2022: Amylyx: Future Looks Good After Surprise Approval, But Unpredictable, Too_ seekingalpha.com
2022: FDA approves ALS drug from Amylyx, giving patients a much-needed treatment option_statnews
2023: Amylyx Pharmaceuticals: A Compelling Buy In The Biotech Sector_seekingalpha.com
2023: Amylyx Pharmaceuticals: Balancing Growth And Market Challenges (Rating Downgrade)_ seekingalpha.com
2024: Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications
2024: Amylyx Pivots to GLP-1 Space, Acquires Phase III-Ready Asset from Eiger
2024: Amylyx readies for make-or-break PhIII, looking to address uncertainty over controversial ALS drug
2024: Amylyx to pull failed ALS drug Relyvrio from market, cut 70% of staffers
2024: Amylyx, with GLP-1 buy, doubles down on blood sugar drugs
2024: Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along
2025: Amylyx Pharmaceuticals: Lots Of Setbacks, Some Chances Of Recovery_ seekingalpha.com
Jumps
Finance & Acquisitions: Amylyx Pharmaceuticals
Key People: Amylyx Pharmaceuticals